^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    elevenostat (JB3-22)

    i
    Other names: JB3-22
    Company:
    BioVision
    Drug class:
    HDAC11 inhibitor
    4years
    Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. (PubMed, JCI Insight)
    Elevenostat demonstrated nanomolar ex vivo activity in 34 MM patient specimens and synergistic activity when combined with bortezomib. Collectively, our data indicate that HDAC11 is an emerging therapeutic vulnerability in MM by targeting an essential pathway in PC biology.
    Journal
    |
    HDAC11 (Histone Deacetylase 11)
    |
    bortezomib • elevenostat (JB3-22)